close
References
  1. Horwitz ME, Stiff PJ, Cutler C, et al. Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. Blood. 2021;138(16):1429-1440.
  2. Wei AH, Breccia M, Ooi M, et al. Preliminary results from a phase 1b study exploring MDM2 inhibitor siremadlin (HDM201) in combination with B-cell lymphoma-2 (BCL-2) inhibitor venetoclax in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS). Presented December 11, 2021 at the 63rd American Society of Hematology Annual Meeting. Abstract 1283.
  3. Pullarkat V, Levis M, Mannis G, et al. Preliminary results by age group of treatment with CPX-351 plus venetoclax in adults with newly diagnosed AML: subgroup analysis of the V-FAST phase 1b master trial. Presented December 11, 2021 at the 63rd American Society of Hematology Annual Meeting. Abstract 1268.
  4. Daver N, Aribi A, Montesinos P, et al. Safety and efficacy from a phase 1b/2 study of IMGN632 in combination with azacitidine and venetoclax for patients with CD123-positive acute myeloid leukemia. Presented December 12 at the 63rd American Society of Hematology Annual Meeting. Abstract 372.
  5. Garcia-Manero G, Erba H, Sanikommu S, et al. Evorpacept (ALX148), a CD47-blocking myeloid checkpoint inhibitor, in combination with azacitidine: a phase 1/2 study in patients with myelodysplastic syndrome. Presented December 12, 2021 at the 63rd American Society of Hematology Annual Meeting. Abstract 2601.
  6. Advani AS, Moseley A, O’Dwyer KM, et al. A phase 2 study of dasatinib, prednisone, and blinatumomab for older patients with Philadelphia-chromosome (Ph) positive or Ph-like acute lymphoblastic leukemia (ALL) with dasatinib-sensitive fusions/mutations. Presented December 13, 2021 at the 63rd American Society of Hematology Annual Meeting. Abstract 3397.